| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease.
|
N Engl J Med
|
2009
|
17.17
|
|
2
|
Cyclosporine before PCI in Patients with Acute Myocardial Infarction.
|
N Engl J Med
|
2015
|
5.90
|
|
3
|
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
|
N Engl J Med
|
2007
|
5.37
|
|
4
|
The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease.
|
EuroIntervention
|
2005
|
5.16
|
|
5
|
Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial.
|
Lancet
|
2013
|
4.34
|
|
6
|
Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk.
|
N Engl J Med
|
2015
|
3.81
|
|
7
|
Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II.
|
Lancet
|
2013
|
3.41
|
|
8
|
Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial.
|
Eur Heart J
|
2011
|
3.29
|
|
9
|
Primary percutaneous coronary intervention in patients with acute myocardial infarction, resuscitated cardiac arrest, and cardiogenic shock: the role of primary multivessel revascularization.
|
JACC Cardiovasc Interv
|
2013
|
2.75
|
|
10
|
Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial.
|
Lancet
|
2011
|
2.67
|
|
11
|
Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial.
|
Lancet
|
2008
|
2.57
|
|
12
|
Transcatheter aortic valve implantation for patients with severe bicuspid aortic valve stenosis.
|
Circ Cardiovasc Interv
|
2013
|
2.26
|
|
13
|
Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents.
|
J Am Coll Cardiol
|
2010
|
2.24
|
|
14
|
Assessment of the SYNTAX score in the Syntax study.
|
EuroIntervention
|
2009
|
2.24
|
|
15
|
Cause of death with bare metal and sirolimus-eluting stents.
|
Eur Heart J
|
2006
|
2.04
|
|
16
|
Transfemoral aortic valve implantation new criteria to predict vascular complications.
|
JACC Cardiovasc Interv
|
2011
|
1.91
|
|
17
|
Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial.
|
Circulation
|
2002
|
1.82
|
|
18
|
Cutting balloon versus conventional balloon angioplasty for the treatment of in-stent restenosis: results of the restenosis cutting balloon evaluation trial (RESCUT).
|
J Am Coll Cardiol
|
2004
|
1.77
|
|
19
|
Incidence, predictors and outcomes of incomplete revascularization after percutaneous coronary intervention and coronary artery bypass grafting: a subgroup analysis of 3-year SYNTAX data.
|
Eur J Cardiothorac Surg
|
2011
|
1.77
|
|
20
|
Quantitative angiographic methods for bifurcation lesions: a consensus statement from the European Bifurcation Group.
|
Catheter Cardiovasc Interv
|
2009
|
1.74
|
|
21
|
Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial.
|
Circulation
|
2005
|
1.64
|
|
22
|
Prognostic value of chronic kidney disease after transcatheter aortic valve implantation.
|
J Am Coll Cardiol
|
2013
|
1.55
|
|
23
|
Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials.
|
Lancet
|
2013
|
1.53
|
|
24
|
Effect of gender differences on early and mid-term clinical outcome after percutaneous or surgical coronary revascularisation in patients with multivessel coronary artery disease: insights from ARTS I and ARTS II.
|
EuroIntervention
|
2009
|
1.48
|
|
25
|
Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights from the RAVEL Trial.
|
Eur Heart J
|
2004
|
1.47
|
|
26
|
Stenting of bifurcation lesions using the Bestent: a prospective dual-center study.
|
Catheter Cardiovasc Interv
|
2002
|
1.46
|
|
27
|
Six-month outcome of emergency percutaneous coronary intervention in resuscitated patients after cardiac arrest complicating ST-elevation myocardial infarction.
|
Circulation
|
2007
|
1.45
|
|
28
|
Duration of balloon inflation for optimal stent deployment: five seconds is not enough.
|
Catheter Cardiovasc Interv
|
2012
|
1.43
|
|
29
|
2-year outcome of patients treated for bifurcation coronary disease with provisional side branch T-stenting using drug-eluting stents.
|
JACC Cardiovasc Interv
|
2008
|
1.43
|
|
30
|
Analysis of stroke occurring in the SYNTAX trial comparing coronary artery bypass surgery and percutaneous coronary intervention in the treatment of complex coronary artery disease.
|
JACC Cardiovasc Interv
|
2013
|
1.42
|
|
31
|
Transcatheter aortic valve implantation in patients of small body size.
|
Catheter Cardiovasc Interv
|
2014
|
1.42
|
|
32
|
Impact of platelet glycoprotein IIb/IIIa receptor inhibitors on outcomes of diabetic patients undergoing percutaneous coronary interventions using sirolimus-eluting stents.
|
Catheter Cardiovasc Interv
|
2008
|
1.39
|
|
33
|
Triple vessel stenting for triple vessel coronary disease.
|
J Invasive Cardiol
|
2002
|
1.38
|
|
34
|
Use of a deflectable tip catheter to facilitate complex interventions beyond insertion of coronary bypass grafts: three case reports.
|
Catheter Cardiovasc Interv
|
2007
|
1.38
|
|
35
|
Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial.
|
Eur J Cardiothorac Surg
|
2013
|
1.24
|
|
36
|
5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions.
|
J Am Coll Cardiol
|
2010
|
1.21
|
|
37
|
Impact of CT-guided valve sizing on post-procedural aortic regurgitation in transcatheter aortic valve implantation.
|
EuroIntervention
|
2012
|
1.19
|
|
38
|
Percutaneous coronary intervention for bifurcation coronary disease.
|
Heart
|
2004
|
1.17
|
|
39
|
Why are we still using coronary bare-metal stents?
|
J Am Coll Cardiol
|
2013
|
1.17
|
|
40
|
Unprotected left main stenting in the real world: two-year outcomes of the French left main taxus registry.
|
Circulation
|
2009
|
1.11
|
|
41
|
Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2.
|
Circ Cardiovasc Interv
|
2009
|
1.11
|
|
42
|
Nine-month outcome of patients treated by percutaneous coronary interventions for bifurcation lesions in the recent era: a report from the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial.
|
J Am Coll Cardiol
|
2005
|
1.10
|
|
43
|
The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase.
|
Am Heart J
|
2006
|
1.10
|
|
44
|
5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
|
J Am Coll Cardiol
|
2009
|
1.07
|
|
45
|
Long-term follow-up of incomplete stent apposition in patients who received sirolimus-eluting stent for de novo coronary lesions: an intravascular ultrasound analysis.
|
Circulation
|
2003
|
1.02
|
|
46
|
Arterial Revascularisation Therapies Study Part II - Sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions.
|
EuroIntervention
|
2005
|
1.00
|
|
47
|
The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer.
|
EuroIntervention
|
2010
|
0.99
|
|
48
|
A randomized comparison of direct stenting with conventional stent implantation in selected patients with acute myocardial infarction.
|
J Am Coll Cardiol
|
2002
|
0.99
|
|
49
|
Three-year follow-up of the ARTS-II# - sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease.
|
EuroIntervention
|
2008
|
0.98
|
|
50
|
Bypass versus drug-eluting stents at three years in SYNTAX patients with diabetes mellitus or metabolic syndrome.
|
Ann Thorac Surg
|
2011
|
0.98
|
|
51
|
Value of the SYNTAX score for risk assessment in the all-comers population of the randomized multicenter LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) trial.
|
J Am Coll Cardiol
|
2010
|
0.97
|
|
52
|
Renal function-based contrast dosing predicts acute kidney injury following transcatheter aortic valve implantation.
|
JACC Cardiovasc Interv
|
2013
|
0.97
|
|
53
|
Transradial approach for coronary angioplasty in the setting of acute myocardial infarction: a dual-center registry.
|
Catheter Cardiovasc Interv
|
2002
|
0.93
|
|
54
|
Drug-eluting stent for left main coronary artery disease. The DELTA registry: a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.
|
JACC Cardiovasc Interv
|
2012
|
0.93
|
|
55
|
Impact of vessel size on angiographic and clinical outcomes of revascularization with biolimus-eluting stent with biodegradable polymer and sirolimus-eluting stent with durable polymer the LEADERS trial substudy.
|
JACC Cardiovasc Interv
|
2009
|
0.91
|
|
56
|
Sex-related differences in clinical presentation and outcome of transcatheter aortic valve implantation for severe aortic stenosis.
|
J Am Coll Cardiol
|
2012
|
0.91
|
|
57
|
The negative impact of incomplete angiographic revascularization on clinical outcomes and its association with total occlusions: the SYNTAX (Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) trial.
|
J Am Coll Cardiol
|
2012
|
0.90
|
|
58
|
True percutaneous approach for transfemoral aortic valve implantation using the Prostar XL device: impact of learning curve on vascular complications.
|
JACC Cardiovasc Interv
|
2012
|
0.89
|
|
59
|
Value of age, creatinine, and ejection fraction (ACEF score) in assessing risk in patients undergoing percutaneous coronary interventions in the 'All-Comers' LEADERS trial.
|
Circ Cardiovasc Interv
|
2011
|
0.89
|
|
60
|
Impact of post-procedural aortic regurgitation on mortality after transcatheter aortic valve implantation.
|
JACC Cardiovasc Interv
|
2012
|
0.87
|
|
61
|
Favourable effect of statin therapy on early survival benefit at the time of percutaneous coronary intervention for ST-elevation myocardial infarction and shock.
|
EuroIntervention
|
2010
|
0.87
|
|
62
|
Is the volume-outcome relation still an issue in the era of PCI with systematic stenting? Results of the greater Paris area PCI registry.
|
Eur Heart J
|
2006
|
0.86
|
|
63
|
Implantation of the biodegradable polymer biolimus-eluting stent in patients with high SYNTAX score is associated with decreased cardiac mortality compared to a permanent polymer sirolimus-eluting stent: two year follow-up results from the "all-comers" LEADERS trial.
|
EuroIntervention
|
2011
|
0.86
|
|
64
|
The impact of body mass index on the one year outcomes of patients treated by percutaneous coronary intervention with Biolimus- and Sirolimus-eluting stents (from the LEADERS Trial).
|
Am J Cardiol
|
2010
|
0.86
|
|
65
|
The three year follow-up of the randomised "all-comers" trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS).
|
EuroIntervention
|
2011
|
0.86
|
|
66
|
Gender-specific outcomes after sirolimus-eluting stent implantation.
|
J Am Coll Cardiol
|
2007
|
0.86
|
|
67
|
Percutaneous coronary intervention versus bypass surgery for left main coronary artery disease: a meta-analysis of randomised trials.
|
EuroIntervention
|
2011
|
0.85
|
|
68
|
Is EuroSCORE II better than EuroSCORE in predicting mortality after transcatheter aortic valve implantation?
|
Catheter Cardiovasc Interv
|
2013
|
0.85
|
|
69
|
The outcome of bifurcation lesion stenting using a biolimus-eluting stent with a bio-degradable polymer compared to a sirolimus-eluting stent with a durable polymer.
|
EuroIntervention
|
2011
|
0.85
|
|
70
|
The transaortic approach for transcatheter aortic valve implantation: a valid alternative to the transapical access in patients with no peripheral vascular option. A single center experience.
|
Eur J Cardiothorac Surg
|
2013
|
0.85
|
|
71
|
2-year clinical follow-up from the randomized comparison of biolimus-eluting stents with biodegradable polymer and sirolimus-eluting stents with durable polymer in routine clinical practice.
|
JACC Cardiovasc Interv
|
2011
|
0.84
|
|
72
|
Potential mechanism of annulus rupture during transcatheter aortic valve implantation.
|
Catheter Cardiovasc Interv
|
2013
|
0.83
|
|
73
|
Usefulness of creatinine clearance in predicting early and late death after primary angioplasty for acute myocardial infarction.
|
Am J Cardiol
|
2003
|
0.83
|
|
74
|
3-Dimensional bifurcation angle analysis in patients with left main disease: a substudy of the SYNTAX trial (SYNergy Between Percutaneous Coronary Intervention with TAXus and Cardiac Surgery).
|
JACC Cardiovasc Interv
|
2010
|
0.82
|
|
75
|
One-year results of coronary revascularization in diabetic patients with multivessel coronary artery disease.Sirolimus stent vs. coronary artery bypass surgery and bare metal stent: insights from ARTS-II and ARTS-I.
|
EuroIntervention
|
2006
|
0.82
|
|
76
|
Rationale and design of the LEADERS FREE trial: A randomized double-blind comparison of the BioFreedom drug-coated stent vs the Gazelle bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy.
|
Am Heart J
|
2013
|
0.81
|
|
77
|
Short- and long-term health related quality-of-life and anginal status of the Arterial Revascularisation Therapies Study part II, ARTS-II; sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease.
|
EuroIntervention
|
2010
|
0.81
|
|
78
|
The CABG SYNTAX Score - an angiographic tool to grade the complexity of coronary disease following coronary artery bypass graft surgery: from the SYNTAX Left Main Angiographic (SYNTAX-LE MANS) substudy.
|
EuroIntervention
|
2013
|
0.81
|
|
79
|
Assessment of left ventricular ejection fraction using the wall motion score index in cardiac magnetic resonance imaging.
|
Arch Cardiovasc Dis
|
2012
|
0.81
|
|
80
|
Risk profile and 3-year outcomes from the SYNTAX percutaneous coronary intervention and coronary artery bypass grafting nested registries.
|
JACC Cardiovasc Interv
|
2012
|
0.81
|
|
81
|
A global risk approach to identify patients with left main or 3-vessel disease who could safely and efficaciously be treated with percutaneous coronary intervention: the SYNTAX Trial at 3 years.
|
JACC Cardiovasc Interv
|
2012
|
0.80
|
|
82
|
ACS and STEMI treatment: gender-related issues.
|
EuroIntervention
|
2012
|
0.80
|
|
83
|
Comparison of 5 French versus 6 French guiding catheters for transradial coronary intervention: a prospective, randomized study.
|
J Invasive Cardiol
|
2004
|
0.80
|
|
84
|
Comprehensive cardiovascular magnetic resonance for diagnosis of cardiac hydatid cyst.
|
Eur Heart J
|
2008
|
0.79
|
|
85
|
Tryton I, First-In-Man (FIM) study: six month clinical and angiographic outcome, analysis with new quantitative coronary angiography dedicated for bifurcation lesions.
|
EuroIntervention
|
2008
|
0.79
|
|
86
|
The coronary artery bypass graft SYNTAX Score: final five-year outcomes from the SYNTAX-LE MANS left main angiographic substudy.
|
EuroIntervention
|
2013
|
0.79
|
|
87
|
Percutaneous aortic valve replacement: new hope for inoperable and high-risk patients.
|
J Invasive Cardiol
|
2007
|
0.78
|
|
88
|
The occupational effects of interventional cardiology: results from the WIN for Safety survey.
|
EuroIntervention
|
2012
|
0.78
|
|
89
|
Are drug-eluting stents safe and effective in the long term?
|
Arq Bras Cardiol
|
2010
|
0.78
|
|
90
|
Automated 3-dimensional aortic annular assessment by multidetector computed tomography in transcatheter aortic valve implantation.
|
JACC Cardiovasc Interv
|
2013
|
0.78
|
|
91
|
Less invasive PTCA of a gastroepiploic artery combining the transradial approach and 5 Fr guiding catheter: a case report.
|
Catheter Cardiovasc Interv
|
2002
|
0.78
|
|
92
|
Tryton I, First-In-Man (FIM) Study: acute and 30 day outcome.A preliminary report.
|
EuroIntervention
|
2007
|
0.78
|
|
93
|
Management of cerebrovascular accidents during cardiac catheterization: immediate cerebral angiography versus early neuroimaging strategy.
|
Catheter Cardiovasc Interv
|
2007
|
0.77
|
|
94
|
Two-year outcomes of everolimus vs. paclitaxel-eluting stent for the treatment of unprotected left main lesions: a propensity score matching comparison of patients included in the French Left Main Taxus (FLM Taxus) and the LEft MAin Xience (LEMAX) registries.
|
EuroIntervention
|
2013
|
0.77
|
|
95
|
Unprotected left main stenting with a second-generation drug-eluting stent: one-year outcomes of the LEMAX Pilot study.
|
EuroIntervention
|
2011
|
0.77
|
|
96
|
Design and rationale for a randomised comparison of everolimus-eluting stents and coronary artery bypass graft surgery in selected patients with left main coronary artery disease: the EXCEL trial.
|
EuroIntervention
|
2016
|
0.77
|
|
97
|
Clinical and angiographic results with the NIR stent: First International NIR Endovascular Stent Study (FINESS-II).
|
Int J Cardiovasc Intervent
|
2000
|
0.77
|
|
98
|
Provisional side branch-stenting for coronary bifurcation lesions: evidence of improving procedural and clinical outcomes with contemporary techniques.
|
Catheter Cardiovasc Interv
|
2013
|
0.77
|
|
99
|
The NUGGET study: NIR ultra gold-gilded equivalency trial.
|
Catheter Cardiovasc Interv
|
2004
|
0.76
|
|
100
|
Evaluating the safety of very short-term (10 days) dual antiplatelet therapy after Genous™ bio-engineered R stent™ implantation: the multicentre pilot Genous trial.
|
EuroIntervention
|
2011
|
0.76
|
|
101
|
Direct stent implantation using the EXPRESS Coronary Stent System: results of a multi-center feasibility study.
|
J Interv Cardiol
|
2003
|
0.76
|
|
102
|
Reply: Challenges in retrospective analysis of PCI data in critically ill patients.
|
JACC Cardiovasc Interv
|
2013
|
0.75
|
|
103
|
Bifurcation lesions: a never-ending challenge.
|
Eur Heart J
|
2008
|
0.75
|
|
104
|
T2 cardiac magnetic resonance in infarct patients: sideman or leader?
|
Arch Cardiovasc Dis
|
2009
|
0.75
|
|
105
|
Polymer-free Drug-Coated Coronary Stents.
|
N Engl J Med
|
2016
|
0.75
|
|
106
|
Unmet needs of young interventional cardiologists: proceedings from the 2nd summit of the European association of percutaneous cardiovascular interventions.
|
EuroIntervention
|
2014
|
0.75
|
|
107
|
Serial intravascular ultrasound observations from the Tryton first-in-man study.
|
EuroIntervention
|
2014
|
0.75
|
|
108
|
Motivations for and barriers to choosing an interventional cardiology career path: results from the EAPCI Women Committee worldwide survey.
|
EuroIntervention
|
2016
|
0.75
|
|
109
|
Influence of technical strategies on the outcome of coronary bifurcation stenting.
|
EuroIntervention
|
2005
|
0.75
|
|
110
|
Revisiting the incidence and temporal distribution of cardiac and sudden death in patients undergoing elective intervention for unprotected left main coronary artery stenosis in the drug eluting stent era.
|
EuroIntervention
|
2007
|
0.75
|
|
111
|
French Ministry of Health prospective multicentre study using bio-active stents coated with titanium nitride oxide: the EVIDENCE registry.
|
Arch Cardiovasc Dis
|
2012
|
0.75
|
|
112
|
Prognostic implications of severe coronary calcification in patients undergoing coronary artery bypass surgery: an analysis of the SYNTAX study.
|
Catheter Cardiovasc Interv
|
2014
|
0.75
|
|
113
|
Biolimus-eluting biodegradable polymer versus sirolimus-eluting permanent polymer stent performance in long lesions: results from the LEADERS multicentre trial substudy.
|
EuroIntervention
|
2009
|
0.75
|
|
114
|
One year results of a new in situ length-adjustable stent platform with a biodegradable biolimus A9 eluting polymer: results of the CUSTOM-II trial.
|
EuroIntervention
|
2008
|
0.75
|
|
115
|
Severe Tako-Tsubo syndrome in the weeks following PCI.
|
Indian Heart J
|
2008
|
0.75
|
|
116
|
The SYNERGY II Everolimus elutiNg stent In patients Older than 75 years undergoing coronary Revascularisation associated with a short dual antiplatelet therapy (SENIOR) trial: rationale and design of a large-scale randomised multicentre study.
|
EuroIntervention
|
2017
|
0.75
|
|
117
|
The Arto transcatheter mitral valve repair system.
|
EuroIntervention
|
2015
|
0.75
|
|
118
|
Long-term outcome of patients with chronic total coronary occlusion treated by percutaneous coronary intervention in diabetics and non-diabetics.
|
EuroIntervention
|
2016
|
0.75
|
|
119
|
Usefulness of a Simple Clinical Risk Prediction Method, Modified ACEF Score, for Transcatheter Aortic Valve Implantation.
|
Circ J
|
2015
|
0.75
|
|
120
|
Unprotected left main stenting in the real world: five-year outcomes of the French Left Main Taxus registry.
|
EuroIntervention
|
2012
|
0.75
|
|
121
|
CMR assessment of AMI patients treated by PCI shows delays in myocardial reperfusion despite initial achievement of TIMI 3 flow.
|
EuroIntervention
|
2005
|
0.75
|
|
122
|
Image. Cardiac magnetic resonance for diagnosis of lipomatous metaplasia of chronic myocardial infarction.
|
Arch Cardiovasc Dis
|
2009
|
0.75
|
|
123
|
Collateral coronary circulation in the absence of obstructive coronary artery disease.
|
J Invasive Cardiol
|
2002
|
0.75
|
|
124
|
Is postdilatation useful after implantation of the Edwards valve?
|
Catheter Cardiovasc Interv
|
2014
|
0.75
|
|
125
|
Five-year outcomes of staged percutaneous coronary intervention in the SYNTAX study.
|
EuroIntervention
|
2015
|
0.75
|
|
126
|
Does geographical variability influence 5-year MACCE rates in the multicenter SYNTAX revascularization trial?
|
EuroIntervention
|
2017
|
0.75
|
|
127
|
Stent supported angioplasty for coronary arterial stenosis following the arterial switch operation.
|
Catheter Cardiovasc Interv
|
2002
|
0.75
|
|
128
|
Successful angioplasty of tripolar renal arteries in a single setting: a case report.
|
J Invasive Cardiol
|
2002
|
0.75
|
|
129
|
Five-year outcomes of chronic total occlusion treatment with a biolimus A9-eluting biodegradable polymer stent versus a sirolimus-eluting permanent polymer stent in the LEADERS all-comers trial.
|
Cardiol J
|
2016
|
0.75
|
|
130
|
'Fused-Gold' vs. 'Bare' stainless steel NIRflex stents of the same geometric design in diseased native coronary arteries. Long-term results from the NIR TOP Study.
|
EuroIntervention
|
2007
|
0.75
|
|
131
|
Delayed and recurrent cardiac tamponade following distal coronary perforation of hydrphilic guidewires during coronary intervention.
|
J Invasive Cardiol
|
2008
|
0.75
|
|
132
|
Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELTA registry: a multicentre registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.
|
EuroIntervention
|
2016
|
0.75
|
|
133
|
Evaluation of a crystalline sirolimus-eluting coronary stent with a bioabsorbable polymer designed for rapid dissolution: two-year outcomes from the DESSOLVE I and II trials.
|
EuroIntervention
|
2016
|
0.75
|
|
134
|
Reproducibility and factors influencing the assessment of the SYNTAX score in the left main Xience study.
|
Catheter Cardiovasc Interv
|
2012
|
0.75
|
|
135
|
Physicians, the medical device industry and the data; a healthy relationship?
|
EuroIntervention
|
2006
|
0.75
|
|
136
|
Polymer-Free Drug-Coated Coronary Stents Are Cost-Effective in Patients at High Bleeding Risk: Economic Evaluation of the LEADERS FREE Trial.
|
EuroIntervention
|
2017
|
0.75
|
|
137
|
Transfemoral aortic valve implantation in patients with an annulus dimension suitable for either the Edwards valve or the CoreValve.
|
Am J Cardiol
|
2013
|
0.75
|